Dr Reddys Laboratories (RDY) Liabilities and Shareholders Equity (2012 - 2026)

Dr Reddys Laboratories' Liabilities and Shareholders Equity history runs 14 years deep, the most recent figure standing at $6.3 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 11.32% year-over-year to $6.3 billion; the TTM figure through Mar 2026 stood at $12.6 billion (up 11.51% YoY), while the FY2026 annual figure was $6.6 billion, up 12.53% from the prior year.
• Liabilities and Shareholders Equity was $6.3 billion for Q1 2026 at Dr Reddys Laboratories, up from $6.2 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $6.3 billion in Q1 2026 to a low of $3.6 billion in Q3 2022.
• Historically, Liabilities and Shareholders Equity has averaged $4.9 billion across 5 years, with a median of $4.7 billion in 2024.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity decreased 2.9% in 2022, then soared 32.52% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $3.6 billion in 2022, then advanced by 15.02% to $4.2 billion in 2023, then jumped by 32.52% to $5.6 billion in 2024, then gained by 11.7% to $6.2 billion in 2025, then climbed by 1.99% to $6.3 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $6.3 billion (Q1 2026), $6.2 billion (Q3 2025), and $5.7 billion (Q1 2025), per Business Quant data.